These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 3954382)
41. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer]. Nio Y; Tobe T Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1436-8. PubMed ID: 2586435 [TBL] [Abstract][Full Text] [Related]
42. [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer]. Mano T; Kawamoto K; Miyake T; Torigoe T Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1439-45. PubMed ID: 2685142 [TBL] [Abstract][Full Text] [Related]
43. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy]. Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664 [TBL] [Abstract][Full Text] [Related]
44. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells]. Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309 [TBL] [Abstract][Full Text] [Related]
45. [Induction of tumor necrosis factor (TNF) by OK-432]. Watanabe N; Sone H; Neda H; Niitsu Y; Urushizaki I Gan No Rinsho; 1984 Aug; 30(10):1290-2. PubMed ID: 6481965 [TBL] [Abstract][Full Text] [Related]
46. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells]. Ishida N; Saito M; Nanjo M Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321 [TBL] [Abstract][Full Text] [Related]
47. Inhalation therapy using a streptococcal preparation (OK-432) against bronchioloalveolar carcinoma of the lung. Yano T; Ichinose Y; Yokoyama H; Fukuyama Y; Sugio K; Sugimachi K Anticancer Res; 1999; 19(6C):5511-4. PubMed ID: 10697608 [TBL] [Abstract][Full Text] [Related]
48. [Partial response of lung metastases from a renal cancer treated with endogenous tumor necrosis factor]. Kato M; Ishiwata D; Kakehi R; Oshima N; Soma G; Mizuno D Gan To Kagaku Ryoho; 1987 Jul; 14(7):2378-80. PubMed ID: 3606157 [TBL] [Abstract][Full Text] [Related]
49. [Tumor growth inhibitory factor (S) produced by lymphocytes in cancer patients with long-term OK-432 therapy]. Katano M Nihon Shokakibyo Gakkai Zasshi; 1986 Sep; 83(9):2088. PubMed ID: 2432298 [No Abstract] [Full Text] [Related]
50. [Clinical investigation of intratumoral OK-432 administration]. Shimada K; Tabuse K; Kono N; Katsumi M; Yamamoto H; Yamamoto Y; Endo A Gan To Kagaku Ryoho; 1983 Aug; 10(8):1844-9. PubMed ID: 6882008 [TBL] [Abstract][Full Text] [Related]
51. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer]. Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507 [TBL] [Abstract][Full Text] [Related]
52. The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: the possible role of a tumor growth inhibitory factor (TGIF). Katano M; Mizoguchi T; Yamamoto H; Nakamura M; Matsuo T; Hisatugu T; Kisu T; Yamaoka K; Tokunaga O Jpn J Surg; 1990 Jan; 20(1):76-82. PubMed ID: 2304290 [TBL] [Abstract][Full Text] [Related]
54. [Nursing of a patient with ascites being treated with OK-432]. Yamashita I; Hidaka M; Ikegawa H; Yuhara K; Mori C Kango Gijutsu; 1989 Mar; 35(4):412-5. PubMed ID: 2754876 [No Abstract] [Full Text] [Related]
55. Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients. Ohwada S; Ogawa T; Izumi M; Inoue T; Teshigawara O; Ikeya T; Kusaba T; Roppongi T; Iino Y; Morishita Y Anticancer Res; 1997; 17(3C):2313-8. PubMed ID: 9216708 [TBL] [Abstract][Full Text] [Related]
56. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients. Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458 [TBL] [Abstract][Full Text] [Related]
57. Successful treatment of ruptured hepatocellular carcinoma with intraperitoneal injection of OK-432. Shiratori M; Nagashima I; Takada T; Morofuji S; Motomiya H; Matsuda K; Inaba T; Fukushima J; Okinaga K J Hepatobiliary Pancreat Surg; 2004; 11(6):426-9. PubMed ID: 15619020 [TBL] [Abstract][Full Text] [Related]
58. [Modulation of anticancer effects of immunochemotherapeutic agents in various nutritional environments]. Akimoto M; Nishihira T; Mori S Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):827-33. PubMed ID: 3260467 [TBL] [Abstract][Full Text] [Related]
59. Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I Immunopharmacology; 1986 Apr; 11(2):79-86. PubMed ID: 3710767 [TBL] [Abstract][Full Text] [Related]
60. [Non-specific immunotherapy with OK-432, streptococcus pyogenes preparation, for inoperable cancer patients of the digestive tract]. Hanaue H; Nomoto S; Yoshizaki S; Kitano Y; Miyakawa S; Horie F; Kurosawa T; Nemoto A; Yasuda H; Takada T Nihon Gan Chiryo Gakkai Shi; 1984 Jul; 19(6):1307-14. PubMed ID: 6512346 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]